OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity

Neurology

Volumn 81, Issue 9, 2013, Pages 841-848

  Chancellor, Michael B ^a   Patel, Vaishali ^b   Leng, Wendy W ^c   Shenot, Patrick J ^d   Lam, Wayne ^b   Globe, Denise R ^b   Loeb, Alex L ^e   Chapple, Christopher R ^f  

^a OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

^c Urology Associates of North Texas   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Evidence Scientific Solutions   (United States)

^f ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; ARTICLE; AVOIDANCE BEHAVIOR; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GOAL ATTAINMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROGENIC BLADDER; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE INCONTINENCE;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 84884470486     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a2ca4d     Document Type: Article

References (18)

1. Hollingworth W, Campbell JD, Kowalski J, et al. Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Qual Life Res 2010;19:323-331.
2. Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007;52:850-858.
3. Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 2007;88: 646-652.
4. Stohrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81-88.
5. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006.
6. Campbell UB, Stang P, Barron R. Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health 2008; 11:726-732.
7. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196-200.
8. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA in patients with urinary incontinence resulting from neurogenic detrusor overactivity. J Urol 2012;187:2131-2139.
9. Cruz F, Herschorn S, Heesakkers J, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:742-750.
10. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 2011;305:89-90.
11. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-415.
12. Sissins P, Barron R. Reliability and validity of the Overactive Bladder-Patient Satisfaction with Treatment Questionnaire (OAB-PSTQ). Qual Life Res 2005;14:2032.
13. Barron R, Sissins P. Development of a patient satisfaction with treatment questionnaire for overactive bladder (OABPSTQ). Qual Life Res 2005;14:2144.
14. Brubaker L, Gousse A, Sand P, et al. Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J 2012;23:1017-1025.
15. Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn 2013;32: 242-249.
16. Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 2006;85:536-545.
17. Fowler CJ, Auerbach S, Ginsberg D, et al. Botulinum toxin A (BOTOX) demonstrates dose-dependent improvements in health-related quality-of-life measures in idiopathic overactive bladder. J Urol 2009;181:558. Abstract LBA8.
18. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-87.